NCT06084689撤回2 期
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 120
- 试验地点
- 6
- 主要终点
- Disease control rate (DCR)
研究概览
简要总结
Phase II, multicenter, open-label, multi-cohort proof-of-concept study designed to evaluate the safety and efficacy of Ezabenlimab combined with BI 907828 in patients with unresectable, locally advanced or metastatic solid tumors.
详细描述
This study is a phase II, multicenter, open-label, multi-cohort proof-of-concept study designed to evaluate the safety and efficacy of Ezabenlimab combined with BI 907828 in patients with unresectable, locally advanced or metastatic solid tumors.
Inclusions will proceed independently for 2 cohorts of patients with TP53 wild-type and TLS+ tumors (TLS: tertiary lymphoid strucutres), as follows:
-
Cohort A: soft-tissue sarcomas
-
Single-arm phase II trial
-
2-stage optimal Simon's design (Simon, 1989)
-
Primary endpoint: is Disease Control Rate (DCR) within 24 weeks of treatment onset, as per RECIST v1.1.
-
Cohort B: Solid tumors [non-small cell lung cancer (NSCLC) or triple negative breast cancer (TNBC) or MMS colorectal cancer (MSS-CCR) or biliary tract cancer (BTC)]
-
Single-arm phase II trial
-
2-stage optimal Simon's design (Simon, 1989)
-
Primary endpoint: is Disease Control Rate (DCR) within 24 weeks of treatment onset, as per RECIST v1.1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis:
- •For cohort A: soft-tissue sarcoma. As recommended by the French NCI, diagnosis must be reviewed or confirmed by the RRePS Network (Réseau de référence en pathologie des sarcomes et des viscères) as recommended by the French NCI (Institut National du Cancer, Inca).
- •For cohort B: non-small cell lung cancer (NSCLC) or triple negative breast cancer (TNBC) or MMS colorectal cancer (MSS-CCR) or biliary tract cancer (BTC)
- •Age ≥ 18 years,
- •Advanced/unresectable and/or metastatic disease,
- •Mature TLS positive status
- •TP53-wild type status known (by molecular biology)
- •Cohort A: MDM2 status known at the time of inclusion
- •Cohort B: are eligible the following populations
- •NSCLC known PD-L1 tumor proportion score (TPS) < 50% AND naïve from treatment with ICI (immune checkpoint inhibitors)
- •NSCLC exposed to anti-PD1 or PD-L1 based therapy with clinical benefit (clinical benefit is defined as objective response or stable disease for at least 4 months)
- •TNBC exposed to anti-PD1 or PD-L1 based therapy with clinical benefit (clinical benefit is defined as objective response or stable disease for at least 4 months)
- •MSS-CCR naïve from treatment with ICI
- •Biliary tract cancer exposed to anti-PD1 or PD-L1 based therapy with clinical benefit (clinical benefit is defined as objective response or stable disease for at least 4 months)
- •Patients must have measurable disease (lesion in previously irradiated filed can be considered as measurable if progressive at inclusion according to RECIST v1.1) defined as per RECIST v1.1 with at least one lesion that can be measured in at least one dimension (longest diameter to be recorded) as > 10 mm with spiral CT scan.,
- •Performance status 0-2
- •Life expectancy ≥ 8 weeks,
- •Adequate hematologic and end-organ function as defined per protocol
- •Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment
- •Recovery to grade ≤ 1 from any adverse event (AE) derived from previous treatment (excluding alopecia and vitiligo of any grade and non-painful peripheral neuropathy grade ≤ 2) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 5.0),
- •Ability to comply with the study protocol, in the investigator's judgment
- •Female subjects of childbearing potential must have a negative serum pregnancy test within 14 days prior to the first dose of study treatment. Serum or urine pregnancy test must be repeated within 72 hours prior to receiving the first dose of study medication,
- •Both women of childbearing potential and men must agree to use two medically acceptable methods of contraception throughout the treatment period
- •No prior or concurrent malignant disease diagnosed or treated in the last 2 years except for: a. superficial/non-invasive bladder cancer, or basal or squamous cell carcinoma in situ treated with curative intent; b. endoscopically resected GI cancers limited to the mucosal layer without recurrence in > 1 year,
- •Voluntarily signed and dated written informed consent prior to any study specific procedure,
- •Patients with a social security in compliance with the French law.
排除标准
- •Prior treatment with ezabenlimab and/or BI 907828,
- •Women who are pregnant or breast feeding,
- •Participation to a study involving a medical or therapeutic intervention in the last 30 days,
- •Previous enrolment in the present study,
- •Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons,
- •Inability to swallow,
- •History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins,
- •Known hypersensitivity to Chinese hamster ovary cell products or to any component of the ezabenlimab or BI 907828 formulation,
- •Symptomatic or actively progressing central nervous system (CNS) metastases.
- •History of leptomeningeal disease,
- •Primary CNS tumors with any of the following characteristics:
- •History of intracranial hemorrhage or spinal cord hemorrhage
- •Neurosurgical resection or brain biopsy to the primary brain tumor within 28 days of Cycle 1 Day 1
- •Any systemic anticancer treatment within 2 weeks or 5 half-lives (whichever is shorter) prior to start of ezabenlimab combined with BI 907828,
- •Whole brain radiotherapy within 14 days prior to start of BI 754091 combined with BI 907828
- •Stereotactic radiosurgery within 7 days prior to start of ezabenlimab combined with BI 907828
- •Active bleeding, significant risk of haemorrhage (e.g. previous severe gastrointestinal bleeding, previous haemorrhagic stroke at any time), or current bleeding disorder (e.g. haemophilia, von Willebrand disease)
- •History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study or confounds the ability to interpret data from the study
- •Incomplete recovery from any surgery prior to the start of ezabenlimab combined with BI 907828 that would interfere with the determination of safety or efficacy of ezabenlimab combined with BI 907828
- •Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina
- •Uncontrolled tumor-related pain.
- •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).
- •Active or history of autoimmune disease or immune deficiency,
- •History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
- •Active tuberculosis
- •Severe infection within 4 weeks prior to initiation of ezabenlimab combined with BI 907828, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
- •Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of ezabenlimab combined with BI
- •Prior allogeneic stem cell or solid organ transplantation
- •Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of ezabenlimab combined with BI 907828, or anticipation of need for such a vaccine during treatment or within 6 months after the final dose ezabenlimab combined with BI
- •Seasonal flu vaccines that do not contain a live virus are permitted,
- •Current treatment with anti-viral therapy for HBV
- •Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives (whichever is longer) prior to initiation of ezabenlimab combined with BI 907828
- •Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of ezabenlimab combined with BI 907828, or anticipation of need for systemic immunosuppressive medication during ezabenlimab combined with BI
- •Patients with oral anticoagulation based on Vitamin K antagonist.
研究组 & 干预措施
Cohort A: soft-tissue sarcomas
Experimental
Soft-tissue sarcomas
干预措施: Ezabenlimab + BI907828 (Drug)
Cohort B: Solid tumors
Experimental
Solid tumors [non-small cell lung cancer (NSCLC) or triple negative breast cancer (TNBC) or MMS colorectal cancer (MSS-CCR) or biliary tract cancer (BTC)]
干预措施: Ezabenlimab + BI907828 (Drug)
结局指标
主要结局
Disease control rate (DCR)
时间窗: 6 months
Disease control rate (DCR), defined as the proportion of patients with disease control lasting for at least 24 weeks since treatment onset, will be reported.
次要结局
- Objective response rate(6 months)
- Duration of response (DoR)(1 year)
- Safety and tolerability of the combination(Throughout treatment period, an expected average of 6 months)
- Progression-free survival (PFS)(1 year)
- Overall survival(1 year)
研究者
研究点 (6)
Loading locations...
相似试验
撤回
2 期
Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid StructuresMetastatic Cancer LungCBNPC CancerAdvanced Lung CancerNCT06713798Gustave Roussy, Cancer Campus, Grand Paris115
Unknown
1 期
Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic MelanomaMelanoma BRAF V600E/K MutatedCDNKN2A Loss DefinedNCT02202200Assistance Publique - Hôpitaux de Paris40
终止
2 期
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal AdenocarcinomaMalignant Solid NeoplasmMetastatic Colorectal AdenocarcinomaMetastatic Ovarian CarcinomaMetastatic Pancreatic Ductal AdenocarcinomaPlatinum-Resistant Ovarian CarcinomaRecurrent High Grade Ovarian Serous AdenocarcinomaRecurrent Ovarian CarcinosarcomaRefractory Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8NCT03610490M.D. Anderson Cancer Center16
招募中
1 期
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILSMetastatic Triple-Negative Breast CarcinomaNCT05451784Fundacio Clinic Barcelona20
终止
2 期
Efficacy of MT-401 in Patients With AML Following Stem Cell TransplantStem Cell TransplantationAcute Myeloid LeukemiaNCT04511130Marker Therapeutics, Inc.92